



March 26, 2021

The Honorable Jim Wood, Chair  
Assembly Committee on Health  
California State Capitol, Room 6005  
Sacramento, CA 95814

**RE: SUPPORT FOR AB 752 (NAZARIAN) PATIENT CHOICE AND TRANSPARENCY ACT**

Dear Chairman Wood,

On behalf of the Hemophilia Council of California, I am writing in strong support of AB 752 (Nazarian) or the Patient Choice and Transparency Act. AB 752 makes prescription drug cost information available at the point-of-care, preventing delays in care and medication nonadherence for the patient while reducing administrative burden on providers. This bill will improve access to quality, affordable health care for people with rare and chronic conditions and diseases.

The Hemophilia Council of California is a 501(c)3 nonprofit organization focused on improving access to care and treatment options to advance the quality of life for people with bleeding disorders through advocacy, education, and outreach in collaboration with its founding member organizations. We aim to increase access to quality innovative care and choice of treatment for all people with bleeding disorders.

Unfortunately, patients must make decisions about their healthcare based on what they can afford. Yet oftentimes, this information is not available until after they reach the pharmacy counter, where they may realize the treatment is unaffordable and may abandon the medication altogether. Delays in care not only worsen the patient's state of health, but also lead to increased utilization of more costly healthcare services later. This is a system that does not work for the patient or our healthcare providers, who are then burdened with added administrative responsibilities. At a time when families are financially struggling due to the COVID-19 pandemic, it is critical to adopt practical changes that improve affordability by freeing up existing drug cost data for patients while reducing strain on pharmacists and physicians.

AB 752 moves prescription drug cost and coverage information into the workflow at the time of prescribing in the physician's office. AB 752 enables decision-making to occur where it should – between a patient and their physician. Patients would be central, active stakeholders in their own health and would be more likely to stick with their treatment plan. This bill is critical and timely to ease up time-consuming and frustrating processes that weigh on patients and their providers and will improve access to quality care for people with chronic disease.

HCC is proud to support AB 752. It will furnish real time information and transparency in workflow and allow consumers to gain information they need to make informed choices, increase access to their care, and alleviate burdens on physicians and providers. Please contact me at: [lkinst@hemophiliaca.org](mailto:lkinst@hemophiliaca.org).

Sincerely,

Lynne Kinst  
Executive Director  
Hemophilia Council of California

cc: Assemblymember Adrin Nazarian (author)  
Assemblymembers: Marie Waldron, Rob Bonta (co-authors)  
Senator Scott Wiener (co-author)  
Members Assembly Health Committee  
Tam Ma, Office of the Governor